UNSPSC 51102858: Hydrocortisone/polymyxin b

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class OT250. This VA Drug Class (OT250) classifies this compound as belonging to the group ANTI-INFECTIVE/ANTI-INFLAMMATORY COMBINATIONS, TOPICAL OTIC.

UNSPSC 51102858 Hydrocortisone/polymyxin b is a Commodity code, though the recent state and local opportunities tagged under it show little activity directly aligned with the code's nominal pharmaceutical scope. The Illinois Department of Public Health awarded a piggyback pharmaceutical warehouse contract through the MMCAP Infuse consortium to Chartwell Rx LLC in August 2026 for Doxycycline Hyclate and Ciprofloxacin Hydrochloride tablets—antibiotics unrelated to the hydrocortisone/polymyxin b combination. Seminole County, Florida posted an IFB in June 2026 for Naloxone and Safe Drug Deactivation Systems, also outside the code's stated product line. State and local health departments and counties appear to use this code designation for pharmaceutical procurement more broadly, but the recent record does not establish consistent purchasing patterns for hydrocortisone/polymyxin b specifically.

The two opportunities span Florida and Illinois, with response deadlines in mid-2026 and mid-2023 respectively. The Illinois contract, valued at $2,999,999.11 over three years including renewals, was awarded through competitive invitation for bid with quarterly or warehouse-order delivery terms. Seminole County's IFB called for 1,900 units of Naloxone and 800 Safe Drug Deactivation Systems annually with quarterly deliveries and an initial two-year term plus one-year renewal option, with delivery to the Seminole County Community Health Building in Sanford. Neither procurement explicitly required set-aside designations. The code shows sparse recent activity, and the opportunities currently tagged under it do not reflect active demand for hydrocortisone/polymyxin b products; vendors pursuing this code should verify current state and local solicitation data and may find stronger activity under broader pharmaceutical supply or antibiotic-specific classifications.